Akero Therapeutics’ (AKRO) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock. HC Wainwright also issued estimates for Akero Therapeutics’ Q4 2023 earnings at ($1.01) EPS, FY2023 earnings at […]
More Stories
Synairgen (LON:SNG) Stock Price Down 0.9% – What’s Next?
Synairgen plc (LON:SNG – Get Free Report) shares fell 0.9% on Wednesday . The stock traded as low as GBX...
Victoria (LON:VCP) Trading Down 7.8% – Here’s What Happened
Victoria PLC (LON:VCP – Get Free Report) traded down 7.8% on Wednesday . The company traded as low as GBX...
Azincourt Energy (CVE:AAZ) Stock Price Up 50% – Still a Buy?
Shares of Azincourt Energy Corp. (CVE:AAZ – Get Free Report) shot up 50% during mid-day trading on Wednesday . The...
Genus (LON:GNS) Reaches New 1-Year Low – Time to Sell?
Genus plc (LON:GNS – Get Free Report)’s share price hit a new 52-week low on Wednesday . The stock traded...
Southern Empire Resources (CVE:SMP) Shares Up 50% – Time to Buy?
Southern Empire Resources Corp. (CVE:SMP – Get Free Report) shares were up 50% during trading on Wednesday . The stock...
Azincourt Energy (CVE:AAZ) Shares Up 50% – Still a Buy?
Azincourt Energy Corp. (CVE:AAZ – Get Free Report)’s share price shot up 50% during mid-day trading on Wednesday . The...